Cited by 148Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes Management and Education

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion

Bode, Bruce, Weinstein, Richard, Bell, David, McGill, Janet, Nadeau, Daniel, Raskin, Philip, Davidson, Jaime, Henry, Robert, Huang, Won-Chin, Reinhardt, Rickey R.·2002·Diabetes Care

DOI 10.2337/diacare.25.3.439

Open this paper in CoChat — free account

Abstract

Objective To compare the safety and efficacy of insulin aspart (IAsp), buffered regular insulin (BR), and insulin lispro administered by continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes. Research design and methods After completing a 4-week run-in period with BR, 146 adult patients with type 1 diabetes (with pretrial CSII experience) were randomly assigned (2:2:1) to CSII treatment with IAsp, BR, or lispro for 16 weeks in a multicenter, open-label, randomized, parallel-group study. Bolus insulin doses were administered 30 min before meals (BR) or immediately before meals (IAsp or lispro). Results Treatment groups had similar baseline HbA(1c) (7.3% +/- 0.7 for IAsp, 7.5% +/- 0.8 for BR, and 7.3% +/- 0.7 for lispro). After 16 weeks of treatment, HbA1c values were relatively unchanged from baseline, and the mean changes in baseline HbA1c values were not significantly different between the three groups (0.00 +/- 0.51, 0.15 +/- 0.63, and 0.18 +/- 0.84 for the IAsp, BR, and lispro groups, respectively). The rates of hypoglycemic episodes (blood glucose Conclusions Insulin aspart in CSII was as efficacious and well tolerated as BR and lispro and is a suitable insulin for continuous subcutaneous insulin infusion using external pumps.

Integrity signals

Registry

Crossref · 10.2337/diacare.25.3.439

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
Balkau, B., Shipley, M. J., Jarrett, R. J., Pyörälà, K., Pyörälä, M., Forhan, A., & Eschwège, É. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 597
Postprandial Blood Glucose
Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464
Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study
Barrett-Connor, E., & Ferrara, A. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1236 · Cited by 369
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 285
Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects
Mudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1501 · Cited by 276
Self-citation

Show all 26 references

Sorted by citations

Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.
Siebenhofer, A., Plank, J., Berghold, A., Jeitler, K., Horvath, K., Narath, M., Gfrerer, R., & Pieber, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003287.pub4 · Cited by 283
Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Therapy Are Equally Effective in Type 2 Diabetes
Raskin, P., Bode, B. W., Marks, J. B., Hirsch, I. B., Weinstein, R. L., McGill, J. B., Peterson, G. E., Mudaliar, S. R., & Reinhardt, R. R. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2598 · Cited by 248
Self-citation
Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes
Colquitt, J. L., Green, C., Sidhu, M. S., Hartwell, D., & Waugh, N. (2004) · Health Technology Assessment · doi:10.3310/hta8430 · Cited by 249
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 241
ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes
Danne, T., Phillip, M., Buckingham, B. A., Jarosz-Chobot, P. A., Saboo, B., Urakami, T., Battelino, T., Hanås, R., & Ethel Codner, D. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12718 · Cited by 226
The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences
Home, P. D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01580.x · Cited by 212
Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII
Hirsch, I. B., Bode, B. W., Garg, S., Lane, W. S., Sussman, A., Hu, P., Santiago, O. M., Kolaczynski, J. W., & for the Insulin Aspart CSII/MDI Comparison Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.3.533 · Cited by 197
Self-citation
Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
Janež, A., Guja, C., Mitrakou, A., Lalic, N., Tankova, T., Czupryniak, L., Tabák, A. G., Prazny, M., Martinka, E., & Smircic-Duvnjak, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00743-7 · Cited by 177
Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics
Pozzilli, P., Battelino, T., Danne, T., Hovorka, R., Jarosz-Chobot, P. A., & Renard, É. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2653 · Cited by 167
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine
Becker, R. H. A., & Frick, A. D. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00002 · Cited by 161
A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes
Plank, J., Wutte, A., Brunner, G. A., Siebenhofer, A., Semlitsch, B., Sommer, R., Hirschberger, S., & Pieber, T. R. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2053 · Cited by 158
Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life
McMahon, S., Airey, F. L., Marangou, D. A., McElwee, K., Carne, C. L., Clarey, A. J., Davis, E. A., & Jones, T. W. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01359.x · Cited by 150
Insulin treatment in children and adolescents with diabetes
Bangstad, H., Danne, T., Deeb, L. C., Jarosz-Chobot, P. A., Urakami, T., & Hanås, R. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00578.x · Cited by 145
Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus
Plank, J., Siebenhofer, A., Berghold, A., Jeitler, K., Horvath, K., Mrak, P., & Pieber, T. R. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1337 · Cited by 140
Insulin treatment in children and adolescents with diabetes
Danne, T., Bangstad, H., Deeb, L. C., Jarosz-Chobot, P. A., Mungaie, L., Saboo, B., Urakami, T., Battelino, T., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12184 · Cited by 131
Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta‐analysis
Colquitt, J. L., Royle, P., & Waugh, N. R. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01018.x · Cited by 95
Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
Fullerton, B., Siebenhofer, A., Jeitler, K., Horvath, K., Semlitsch, T., Berghold, A., Plank, J., Pieber, T. R., & Gerlach, F. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012161 · Cited by 94
Continuous subcutaneous insulin infusion with short‐acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost‐effectiveness
Radermecker, R. P., & Scheen, A. J. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.447 · Cited by 88
Insulin treatment
Bangstad, H., Danne, T., Deeb, L. C., Jarosz-Chobot, P. A., Urakami, T., & Hanås, R. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00233.x · Cited by 72
Insulin analogues: an example of applied medical science
Sheldon, B., Russell‐Jones, D., & Wright, J. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01015.x · Cited by 69
Technical risks with subcutaneous insulin infusion
Guilhem, I., Leguerrier, A., Lecordier, F., Jy, P., & Maugendre, D. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70281-1 · Cited by 67
Insulin Aspart
Chapman, T. M., Noble, S., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262130-00014 · Cited by 67
Glycemic Control and Selected Pregnancy Outcomes in Type 1 Diabetes Women on Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections: The Significance of Pregnancy Planning
Cyganek, K., Hebda-Szydło, A., Katra, B., SKUPIEN, J. K., Klupa, T., Janas, I., Kaim, I., Sieradzki, J., Reroń, A., & Malecki, M. T. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0081 · Cited by 64
Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: A systematic review
Rys, P., Pankiewicz, O., Lach, K., Kwaskowski, A., Skrzekowska-Baran, I., & Malecki, M. T. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.12.003 · Cited by 64
Stability and Performance of Rapid-Acting Insulin Analogs Used for Continuous Subcutaneous Insulin Infusion: A Systematic Review
Kerr, D. E., Wizemann, E., Senstius, J., Zacho, M., & Ampudia‐Blasco, F. J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700620 · Cited by 62
Laboratory-Based Non-Clinical Comparison of Occlusion Rates Using Three Rapid-Acting Insulin Analogs in Continuous Subcutaneous Insulin Infusion Catheters Using Low Flow Rates
Kerr, D., Morton, J., Whately-Smith, C., Everett, J., & Begley, J. P. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200314 · Cited by 60
Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium
Acerini, C. L., Craig, M. E., de Beaufort, C. E., Maahs, D. M., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12182 · Cited by 59
Novel insulin analogues and its mitogenic potential
Zib, I., & Raskin, P. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00567.x · Cited by 57
Self-citation
A Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion of Insulin Aspart Versus Insulin Lispro in Children and Adolescents With Type 1 Diabetes
WEINZIMER, S. A., Ternand, C. L., Howard, C. P., Chang, C., Becker, D. J., Laffel, L. M., & for the Insulin Aspart Pediatric Pump Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1378 · Cited by 57
Safety of Insulin Glulisine when Given by Continuous Subcutaneous Infusion Using an External Pump in Patients with Type 1 Diabetes
Hoogma, R., & Schumicki, D. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-944549 · Cited by 66
Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues— aspart, lispro, and glulisine
Bode, B. W. (2011) · Endocrine Practice · doi:10.4158/ep10260.ra · Cited by 56
Self-citation
Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control
Radermecker, R. P., Renard, É., & Scheen, A. J. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.961 · Cited by 54
Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy
Siebenhofer, A., Plank, J., Berghold, A., Horvath, K., Sawicki, P. T., Beck, P., & Pieber, T. R. (2004) · Diabetologia · doi:10.1007/s00125-004-1545-x · Cited by 51
Is There a Place for Insulin Pump Therapy in Your Practice?
Skyler, J. S., Ponder, S., Kruger, D. F., Matheson, D., & Parkin, C. G. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.2.50 · Cited by 50
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
Siebenhofer, A., Plank, J., Berghold, A., Narath, M., Gfrerer, R., & Pieber, T. R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003287.pub3 · Cited by 46
Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience
Hermansen, K., Bohl, M., & Schioldan, A. G. (2015) · Drugs · doi:10.1007/s40265-015-0500-0 · Cited by 47
Insulin Aspart
Reynolds, N. A., & Wagstaff, A. J. (2004) · Drugs · doi:10.2165/00003495-200464170-00013 · Cited by 43
Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block
Klonoff, D. C., Freckmann, G., & Heinemann, L. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817700545 · Cited by 41
In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion
DeFelippis, M. R., Bell, M. A., Heyob, J. A., & Storms, S. M. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.358 · Cited by 41
Hypoglycemia in Insulin-Treated Diabetes: A Case for Increased Vigilance
Unger, J., & Parkin, C. G. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2307 · Cited by 41
Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections
Bode, B. W. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.12.013 · Cited by 38
Self-citation
Precipitation of Insulin Products Used for Continuous Subcutaneous Insulin Infusion
Poulsen, C., Langkjær, L., & Worsøe, C. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.142 · Cited by 36
Insulin Lispro
Simpson, D., McCormack, P. L., Keating, G. M., & Lyseng-Williamson, K. A. (2007) · Drugs · doi:10.2165/00003495-200767030-00006 · Cited by 37
Glycemic Management in Adults With Type 1 Diabetes
McGibbon, A., Adams, L., Ingersoll, K. S., Kader, T., & Tugwell, B. D. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.012 · Cited by 42
Diabetes Mellitus Complicating Pregnancy
Landon, M. B., Catalano, P. M., & Gabbe, S. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06930-7.50039-6 · Cited by 36
Exploring plant-based alpha-glucosidase inhibitors: promising contenders for combatting type-2 diabetes
Kumari, S., Saini, R. P., Bhatnagar, A., & Mishra, A. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2262167 · Cited by 34
Contemporary Management of Patients with Type 1 Diabetes
Mehta, S. N., & Wolfsdorf, J. I. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.002 · Cited by 35
Quality of life and metabolic control in patients with diabetes mellitus type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections.
Hoogma, R. P. L. M., Spijker, A. J., van Doorn-Scheele, M., van Doorn, T. T., Michels, R. P. J., van Doorn, R. G., Levi, M. M., & Hoekstra, J. B. L. (2004) · PubMed · Cited by 34
Moving toward the ideal insulin for insulin pumps
Cengiz, E., Bode, B., Van Name, M., & Tamborlane, W. V. (2016) · Expert Review of Medical Devices · doi:10.1586/17434440.2016.1109442 · Cited by 38
Self-citation
Insulin Analog Preparations and Their Use in Children and Adolescents with Type 1 Diabetes Mellitus
Miles, H. L., & Acerini, C. L. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810030-00005 · Cited by 31
Biosimilar insulins: guidance for data interpretation by clinicians and users
Heinemann, L., Home, P., & Hompesch, M. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12491 · Cited by 29
Evidence-based insulin treatment in type 1 diabetes mellitus
Jacobsen, I. B., Henriksen, J. E., Nielsen, O. H., Vach, W., & Beck‐Nielsen, H. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.05.020 · Cited by 29
Unexplained Hyperglycemia in Continuous Subcutaneous Insulin Infusion
Ponder, S. W., Skyler, J. S., Kruger, D. F., Matheson, D., & Brown, B. W. (2008) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721708315682 · Cited by 29
Insulin analogues and other developments in insulin therapy for diabetes
McAulay, V., & Frier, B. M. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.7.1141 · Cited by 28
Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis
Nørgaard, K., Sukumar, N., Rafnsson, S. B., & Saravanan, P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0411-7 · Cited by 26
Precipitation of Insulin Aspart and Insulin Glulisine Products Used for Continuous Subcutaneous Insulin Infusion
Poulsen, C., Langkjær, L., & Worsøe, C. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0054 · Cited by 26
Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente concon diabetes mellitus. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Escalada, J., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.04.005 · Cited by 23
Pharmacological Properties of Faster-Acting Insulin Aspart
Biester, T., Kordonouri, O., & Danne, T. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0931-y · Cited by 23
Insulin aspart: a review
Owens, D. R., & Vora, J. P. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.5.793 · Cited by 23
In Vitro Stability of Insulin Aspart in Simulated Continuous Subcutaneous Insulin Infusion Using a MiniMed® 508 Insulin Pump
Senstius, J., Harboe, E., & Westermann, H. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0041 · Cited by 23
Pharmacotherapy in Type 1 Diabetes
McGibbon, A., Richardson, C., Hernandez, C. A., & Dornan, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.020 · Cited by 22
Patient management of long‐term continuous subcutaneous insulin infusion
Johansson, U., Adamson, U., LINS, P.-E. S., & Wredling, R. (2005) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2005.03475.x · Cited by 20
Cost-effectiveness of insulin analogs.
Brixner, D. I., & McAdam‐Marx, C. (2008) · PubMed · Cited by 20
Insulin pump therapy in type 1 diabetes mellitus
Liberatore, R. D. R., & Damiani, D. (2006) · Jornal de Pediatria · doi:10.2223/jped.1507 · Cited by 19
The safety and efficacy of insulin analogs in pregnancy
Gamson, K., Chia, S., & Jovanovič, L. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650680 · Cited by 19
An estimation of the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK
Pratoomsoot, C., Smith, H. T., Kalsekar, A., Boye, K. S., Arellano, J., & Valentine, W. J. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02775.x · Cited by 18
Insulin analogues versus human insulin in type 1 diabetes: direct and indirect meta-analyses of efficacy and safety
Sanches, A. C. C., Correr, C. J., Venson, R., Gonçalves, P. R., Garcia, M. M., Piantavini, M. S., & Pontarolo, R. (2013) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502013000300011 · Cited by 18
Position statement: Hypoglycemia management in patients with diabetes mellitus. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition
Mezquita‐Raya, P., Reyes‐García, R., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Martínez, J. J. G., Jódar-Gimeno, E., Martín, J. E. S., Gargallo-Fernández, M., Soto-González, A., et al. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2013.11.009 · Cited by 18
Insulin pumps
Torrance, T. (2003) · Archives of Disease in Childhood · doi:10.1136/adc.88.11.949 · Cited by 18
Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions
Lefever, E., Vliebergh, J., & Mathieu, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1856813 · Cited by 16
14-Day In Vitro Chemical Stability of Insulin Lispro in the MiniMed Paradigm Pump
Sharrow, S. D., Glass, L. C., & Dobbins, M. A. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0125 · Cited by 16
Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes.
Weintrob, N., Shalitin, S., & Phillip, M. (2004) · PubMed · Cited by 15
Uso de bomba de infusão subcutânea de insulina e suas indicações
Minicucci, W. J. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000200022 · Cited by 14
Spotlight on Insulin Aspart in Type 1 and 2 Diabetes Mellitus*
Chapman, T. M., Noble, S., & Goa, K. L. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302010-00006 · Cited by 12
BENEFITS OF INSULIN ASPART VS PHOSPHATE-BUFFERED HUMAN REGULAR INSULIN IN PERSONS WITH TYPE 1 DIABETES TREATED BY MEANS OF AN INSULIN PUMP
Chlup, R., Zapletalová, J., Sečkař, P., Chlupová, L., Táncosová, S., & Řezníčková, M. (2004) · Biomedical Papers · doi:10.5507/bp.2004.004 · Cited by 11
Tipos de insulinoterapia
de la Fuente, J. S., Berná, V. G., Piquero, J. M. F., Zanuy, M. Á. V., & López-Coterilla, A. H. D. T. (2008) · Revista Clínica Española · doi:10.1157/13115203 · Cited by 12
Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: Results of double‐blind and open‐label cross‐over trials of insulin lispro and insulin aspart 1型糖尿病患者连续使用胰岛素泵6天后的血糖控制情况：赖脯胰岛素与门冬胰岛素的双盲、开放标签、交叉试验
Tamborlane, W. V., Renard, É., Wadwa, R. P., Blevins, T., Jacober, S. J., Liu, R., D’Souza, D. N., & Rees, T. M. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12162 · Cited by 10
Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
Gao, G.-Q., Heng, X., WANG, Y.-L., Li, W., DONG, Q.-Y., LIANG, C.-G., Du, W., & LIU, X.-M. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1866 · Cited by 10
Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes
Block, C. E. M. D., Cauwenberghe, J. V., Bochanen, N., & Dirinck, E. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14713 · Cited by 10
Treatment of Danish adolescent diabetic patients with CSII - a matched study to MDI
Johannesen, J., Eising, S., Kohlwes, S., Riis, S., Beck, M., Carstensen, B., Bendtson, I., & Nerup, J. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00264.x · Cited by 10
Insulin lispro: a useful advance in insulin therapy
Heller, S. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.8.1407 · Cited by 10
Insulin Aspart: An Evidence-Based Medicine Review
Haycox, A. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424120-00002 · Cited by 9
Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients
Kubo, S., Watada, H., & Kawamori, R. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00011.x · Cited by 8
Pediatric Use of Insulin Pumps: Longer Infusion Site Lifetime With NovoLog
Becker, D. I. (2002) · Diabetes Care · doi:10.2337/diacare.25.9.1663 · Cited by 8
Insulinothérapie Nouvelles molécules et voies d’administration
Verge, D. (2004) · médecine/sciences · doi:10.1051/medsci/20042011986 · Cited by 8
Comparative Effectiveness of Rapid-Acting Insulins in Adults with Diabetes
Racsa, P. N., MEAH, Y. A., Ellis, J. J., & Saverno, K. R. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3.291 · Cited by 8
Evaluation of Treatment Satisfaction Associated with the Use of Insulin Aspart in Continuous Subcutaneous Insulin Infusion
Wittlin, S. D., Marcus, A. O., Weng, C. S. W., Howard, C. P., Schorr, A. B., & for the CONTROL Study Group (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0234 · Cited by 8
In Silico Simulation of Long-Term Type 1 Diabetes Glycemic Control Treatment Outcomes
Wong, X., Chase, J. G., Hann, C. E., Lotz, T., Lin, J., Compte, A. J. L., & Shaw, G. M. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200313 · Cited by 8
Diabetes in Pregnancy
Moore, T. R., & Catalano, P. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4224-2.50049-1 · Cited by 7
The state of insulin pump therapy: 2002
Plodkowski, R. A., & Edelman, S. V. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200208000-00006 · Cited by 7
Comparison of Efficacy and Safety of Lispro and Aspart Evaluated by Continuous Glucose Monitoring System in Patients with Newly Diagnosed Type 2 Diabetes
Liu, B.-L., Yin, G., Li, F.-F., Hu, Y., Wu, J.-D., Chen, M.-Y., Ye, L., Su, X., & Ma, J. (2018) · International Journal of Endocrinology · doi:10.1155/2018/2087960 · Cited by 6
New strategies in insulin treatment: analogues and noninvasive routes of administration
Rungby, J., Brock, B., & Schmitz, O. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00306.x · Cited by 6
Microvascular Consequences of Obesity and Diabetes
Bohlen, H. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374530-9.00021-8 · Cited by 5
Insulin Lispro with Continuous Subcutaneous Insulin Infusion is Safe and Effective in Patients With Type 2 Diabetes: A Randomized Crossover Trial of Insulin Lispro Versus Insulin Aspart
Thrasher, J. R., Bhargava, A., Rees, T. M., Wang, T., Guzmán, C. B., & Glass, L. C. (2014) · Endocrine Practice · doi:10.4158/ep14242.or · Cited by 5
Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
Fogelfeld, L. A., Uy, J., & Guerra, Y. S. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s15404 · Cited by 5
The Insulin Pump
Olohan, K., & Zappitelli, D. (2003) · AJN American Journal of Nursing · doi:10.1097/00000446-200304000-00020 · Cited by 5
DIABETIC MANAGEMENT IN HIGH RISK PATIENTS (PREGNANCY, INSULIN PUMPS)
Vanhaverbeke, G., Mertens, A. C., & Mathieu, C. (2004) · Acta Clinica Belgica · doi:10.1179/acb.2004.026 · Cited by 4
Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?
Bartolo, P. D., Pellicano, F., Scaramuzza, A., Fabbri, T., Melandri, P., Miselli, V., Casetti, T., & Cannatà, F. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(06)70013-4 · Cited by 4
A case of hypoglycemic brittle diabetes with peripheral edema successfully managed by conversion from insulin lispro to insulin aspart
Tone, A., Shikata, K., Nakagawa, K., Hashimoto, M., & Makino, H. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.013 · Cited by 4

Authors: Bode, B., Weinstein, R., Bell, D., McGill, J., Nadeau, D., Raskin, P., Davidson, J., Henry, R., Huang, W.-C., & Reinhardt, R. R.
Affiliations: Atlanta Diabetes Associates (US)
Diablo Clinical Research (US)
Kirklin Clinic (US)
Washington University in St. Louis (US)
Eastern Maine Medical Center (US)
The University of Texas Southwestern Medical Center (US)
Endocrine & Diabetes Associates, Dallas, Texas
VA San Diego Healthcare System (US)
Novo Nordisk Pharmaceuticals, Princeton, New Jersey
ORCID: Bode, Bruce
McGill, Janet
Davidson, Jaime
Henry, Robert
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2002-03-01
Volume: 25
Issue: 3
Pages: 439-444
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.25.3.439
OpenAlex: W2091336973
Cited by: 148
References: 26
Citations by year: 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2020: 3 · 2018: 5 · 2017: 6 · 2016: 1 · 2015: 7 · 2014: 6 · 2013: 10 · 2012: 6
FWCI: 6.65
Type: journal article
Language: en
Open access: closed
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: Novo Nordisk
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords: insulin aspart, insulin lispro, insulin pump therapy, type 1 diabetes, bolus insulin, glycemic control, HbA1c, hypoglycemia, insulin analogues
MeSH terms: Adult, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Safety, Body Mass Index, Insulin Aspart, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks